Vonseca® is the first full range Generic of Vonoprazan In Egypt

Vonseca PCAB Vonoprazan
Vonseca PCAB Vonoprazan
Vonseca PCAB Vonoprazan
Vonseca PCAB Vonoprazan Egypt
Vonoprazan egypt Vonseca

About Vonoprazan & P-CABs

𝐕𝐎𝐍𝐎𝐏𝐑𝐀𝐙𝐀𝐍 is a first-in-class potassium-competitive acid blocker. It was approved in the Japanese market in February 2015.

Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.

𝐈𝐧 𝟎𝟑-𝐌𝐚𝐲-𝟐𝟎𝟐𝟐 The (𝐅𝐃𝐀) has approved 2 𝐕𝐎𝐍𝐎𝐏𝐑𝐀𝐙𝐀𝐍-based medications for the treatment of Helicobacter pylori (H. pylori) infection.

The approval of 𝐕𝐎𝐍𝐎𝐏𝐑𝐀𝐙𝐀𝐍 treatment regimens offers physicians and patients 2 therapeutic options that showed superior eradication rates compared to proton pump inhibitor-based (PPI) lansoprazole triple therapy in the overall patient population in a pivotal trial.

𝐕𝐎𝐍𝐎𝐏𝐑𝐀𝐙𝐀𝐍 belongs to a class of products known as PCAB, or potassium-competitive acid blockers. By blocking the potassium-binding site of gastric hydrogen potassium ATPase (also known as the proton pump), which is the enzyme largely responsible for acidification of the stomach, it’s designed to overcome many of the perceived weaknesses of traditional proton pump inhibitor therapy.

P-CABs Vonoprazan - Vonseca
PCABs Vonoprazan - Vonseca
P-CAB Vonoprazan - Vonseca
PCAB- Vonoprazan- Vonseca

About Vonseca®

As per its commitment to offer the latest treatment for the Egyptian's patients., in Jan 2022 Zeta Pharma was the first Egyptian pharmaceutical company to introduce two concentrations of 10mg and 20 mg of vonoprazan in the Egyptian market through its brand Vonseca.®

Vonseca® Vonoprazan Egypt
Vonseca® Vonoprazan Egypt

About Zeta Pharma

ZETA PHARMA® was established in 2010 to represent an added value in the pharmaceutical industry in Egypt through:
Establishing one of the best manufacturing facilities in the Middle East referenced by the international standards (GMP).
Building a well selected and unique product portfolio in the main therapeutic areas, which ensure that community has the most efficient and up-to-date treatment that directly contributes to improving health care and quality of their life.

Beginning in 2015, ZETA PHARMA® actively contribute to treating Hepatitis C virus in Egypt through its products:
Sofocivir ™, Zetaciver™, Sofocivir plus™


Share on LinkedInShare on Youtube